<DOC>
	<DOCNO>NCT00820703</DOCNO>
	<brief_summary>Diabetic foot ulcer sores foot occur 15 % diabetic patient time lifetime . Once ulcer develops , risk lower-extremity amputation increase 8-fold people diabetes . New treatment improve number ulcer heal and/or speed heal urgently need . Initial study new drug call Nexagon® ( develop CoDa Therapeutics , Inc. ) support concept heal diabetic foot ulcer improve topical application Nexagon® . Further research undertaken assess safety activity Nexagon® apply diabetic foot ulcer various dos . A propose randomized control trial randomly allocate ( e.g. , toss coin ) 24 people diabetic foot ulcer Nexagon® ( one three different dos ) vehicle ( substance contain medication ) apply ulcer three time four week . Participants follow four week monitor response treatment , specifically regard amount healing occur .</brief_summary>
	<brief_title>The ASCEND Study : A Study Investigate Safety Clinical Effect Nexagon Treat Slow Healing Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Male female age 18 old 2 . Female subject must ) postmenopausal , b ) surgically sterilize , c ) practice abstinence , ) use hormonal contraceptive , intrauterine device , diaphragm spermicide condom spermicide duration study 3 . Diabetes mellitus ( type I II ) HbA1c &lt; 10.0 % 4 . Diagnosis neuropathic foot ulcer 5 . Cutaneous , full thickness ( University Texas grade A1 ) , ankle surface ulcer 0.5 5.0 cm2 postdebridement 6 . A viable , granulate wound 7 . Ulcer present &gt; 4 week prior study entry 8 . An ankle brachial index 0.70 1.3 measure screening within three month prior Day 14 visit 9 . Signed informed consent form 1 . Decrease increase ulcer size 30 % a14 day `` runin '' period 2 . Can tolerate offload method comply standardofcare 3 . An ulcer show sign clinical infection 4 . The ulcer treat require operative debridement . 5 . An ulcer positive βhemolytic streptococcus upon culture . 6 . Requirement total contact cast 7 . The ulcer 50 % slough , significant necrotic tissue , osteomyelitis , bone , tendon , capsule exposure 8 . Presence active systemic local cancer tumor kind ( exception nonmelanoma skin cancer ) 9 . Congestive heart failure NYHA class II IV 10 . Coronary heart disease STEMI , CABG , PTCA within last 6 month 11 . Active osteomyelitis study foot 12 . Active connective tissue disease 13 . Acute Charcot 's neuroarthropathy determine clinical and/or radiographic examination 14 . Treatment systemic corticosteroid ( 15 . Previous current radiation therapy distal low extremity likelihood receive therapy study participation 16 . Pregnancy lactation 17. eGFR &lt; 25 mL/min 18 . Poor nutritional status define albumin &lt; 25 g/L 19 . Significant peripheral edema 20 . Known prior inability complete require study visit study participation 21 . A psychiatric condition ( e.g. , suicidal ideation ) chronic alcohol drug abuse problem , determine subject 's medical history , , opinion Investigator , may pose threat subject compliance 22 . Use plateletderived growth factor within 28 day prior screen 23 . Use investigational drug therapy within 28 day prior screen 24 . Any factor may , opinion Investigator , compromise participation followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Nexagon</keyword>
	<keyword>CoDa</keyword>
	<keyword>ulcer</keyword>
	<keyword>diabetic</keyword>
	<keyword>foot</keyword>
</DOC>